4.35
+4.57%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Nuvation Bio
From its filings with the US Securities and Exchange Commission
Nuvation Bio is based in New York, New York and is incorporated in Delaware. Its shares trade on NYSE under the ticker NUVB. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $62.9m and a net loss of $204.6m. At that date it held total assets of $594.8m and shareholders' equity of $305.7m.
On February 10, 2021, (the “Closing Date”), Nuvation Bio Inc., a Delaware corporation (“Legacy Nuvation Bio”), Panacea Acquisition Corp. (“Panacea”), and Panacea Merger Subsidiary Corp, a Delaware corporation and a direct, wholly owned subsidiary of Panacea (“Merger Sub”) consummated the transactions contemplated by an Agreement and Plan of Merger among them dated October 20, 2020 (“Merger Agreement”).
Pursuant to the terms of the Merger Agreement, a business combination of Panacea and Legacy Nuvation Bio was effected through the merger of Merger Sub with and into Legacy Nuvation Bio, with Legacy Nuvation Bio surviving as a wholly owned subsidiary of Panacea (the “Merger”). On the Closing Date, Legacy Nuvation Bio changed its name to Nuvation Bio Operating Company Inc. and Panacea changed its name to Nuvation Bio Inc. (the “Company” or “Nuvation Bio”).
In connection with the closing of the Merger, our Class A common stock and warrants to purchase shares of our Class A common stock began trading on The New York Stock Exchange under the symbols “NUVB” and “NUVB.WS,” respectively, on February 11, 2021. The disclosure in Items 1 and 1A of this report gives effect to the Merger and includes the operations of Legacy Nuvation Bio prior to the Merger.
Quoted from its 10-K, filed 2 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 1 Jul 2020
- Employees
- 298
- Website
- nuvationbio.com ↗
- Head office
- 1500 BROADWAY, NEW YORK, NY, 10036
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. David HungChairman of the Board, President, Chief Executive Officer, Founder, since 2018$3.7m
- Mr. Philippe SauvageChief Financial Officer and Principal Financial Officer
- Mr. David HanleyChief Technical Operations Officer$3.3m
- Ms. Stacy MarkelChief People Officer
- Mr. Moses MakunjePrincipal Accounting Officer, Vice President - Finance
- Dr. Gary HattersleyChief Scientific Officer$1.4m
- Mr. David LiuChief Medical Officer$1.3m
- Ms. Colleen SjogrenChief Commercial Officer$2.2m
- Ms. Kerry WentworthChief Regulatory Officer
- Mr. Robert BazemoreLead Independent Director$446,645
- Mr. Kim BlickenstaffIndependent Director$432,520
- Dr. Xiangmin CuiIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 55
- Environment
- 56
- Social
- 76
- Governance
- 32
- Women in the workforce
- 51%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Nuvation Bio Inc focuses on oncology with novel therapeutic candidates targeting difficult-to-treat cancers.
- NUV-868 is a BD2-selective oral small molecule BET inhibitor targeting BRD4 protein regulation.
- The company employs 53 full-time employees in San Francisco, California, with a strong focus on oncology research.
Weaknesses
- Nuvation Bio Inc has only 53 full-time employees, which may limit research and development capacity.
- The company's clinical-stage product NUV-868 is still in development without approved treatments.
- Nuvation Bio Inc has not yet achieved commercialization of any products as of 2020.
Opportunities
- Nuvation Bio Inc can leverage its DDC platform for new drug-conjugate therapies in oncology.
- The US market offers significant potential for innovative oncology treatments like NUV-868.
- The company's focus on epigenetic regulation of tumor growth could lead to breakthrough therapies.
Threats
- Nuvation Bio Inc faces competition from established pharmaceutical companies in oncology.
- The development of NUV-868 may encounter regulatory hurdles in the US FDA approval process.
- The company's reliance on a single clinical-stage product NUV-868 poses significant business risk.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.